Shares of Lupin Ltd. were trading in the green and 1.8% higher on 21 June after the company’s manufacturing facility in Somerset, New Jersey, received EIR from the US Food and Drug Administration (USFDA). 

In its regulatory filing, the company said, “Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Somerset, New Jersey, with a Voluntary Action Indicated (VAI) status.”

The US regulator conducted an inspection at its Somerset manufacturing facility between 7 May and 17 May 2024.

Nilesh Gupta, Managing Director of Lupin, said, “We are very pleased to have received the EIR with a satisfactory VAI status for our Somerset facility. This is a significant milestone in building our reputation of being best-in-class in Quality and Compliance.”

Earlier, on 12 June, the company signed a licence and supply agreement with OLIC (Thailand) Limited, a subsidiary of Japanese pharmaceutical company Fuji Pharma Co Ltd, to market Nextstellis (drospirenone and estetrol tablets) in Vietnam and the Philippines.

At 1:12 pm, the shares of Lupin were trading 0.63% higher at Rs 1,570.95 on NSE.